Holen Sie sich die Stockscreener-App
6.30
11.52%
-0.82
Handel nachbörslich:
6.39
0.09
+1.43%
CorMedix Inc Aktie (CRMD) Neueste Nachrichten
Truist reiterates CorMedix stock rating on steady guidance - Investing.com India
CorMedix (CRMD) Valuation Check After Recent Share Price Swings And Melinta Acquisition Narrative - simplywall.st
Why Did CRMD Stock Tumble Over 11% Today? - Stocktwits
CorMedix Shares Fall After Q4 Profit Miss - marketscreener.com
CorMedix: Fourth Quarter Financial Results Overview - Bitget
CorMedix (CRMD) Q4 2025 Earnings Call Transcript - The Globe and Mail
CorMedix stock falls after earnings miss (CRMD:NASDAQ) - Seeking Alpha
Earnings call transcript: CorMedix Q4 2025 results miss EPS, stock dips - Investing.com Nigeria
CorMedix (CRMD) Lags Q4 Earnings Estimates - Yahoo Finance
CorMedix Q4 2025 Earnings Call Transcript - MarketBeat
Cormedix Earnings Review: Q4 Summary - Benzinga
CorMedix earnings missed by $0.69, revenue topped estimates - Investing.com
CorMedix: Q4 Earnings Snapshot - KVUE
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance - Investing.com
CORMEDIX ($CRMD) Releases Q4 2025 Earnings - Quiver Quantitative
CorMedix stock falls 5% on fourth quarter earnings miss - Investing.com India
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results - TradingView
CorMedix reports Q4 revenue of $128.6M, reaffirms 2026 guidance By Investing.com - Investing.com UK
CorMedix Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update - The Manila Times
Cormedix Stock Pre-Market (+6.2%) : Technical Move Ahead of Key Q2 Catalyst - Trefis
Cormedix Earnings Preview - Benzinga
CRMD Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Earnings Preview: CorMedix to Report Financial Results Pre-market on March 05 - 富途牛牛
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 5, 2026 - marketscreener.com
CorMedix Inc. to Report Fourth Quarter and Full Year 2025 - GlobeNewswire
Responsive Playbooks and the CRMD Inflection - Stock Traders Daily
CRMD Earnings History & Surprises | EPS & Revenue Results | CORMEDIX INC (NASDAQ:CRMD) - ChartMill
Is It Time To Revisit CorMedix (CRMD) After Its Sharp Year To Date Decline? - Yahoo Finance
CRMD SEC FilingsCormedix 10-K, 10-Q, 8-K Forms - Stock Titan
CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention - Sahm
CorMedix Inc. (CRMD): Investor Outlook With A Promising 102% Upside Potential - DirectorsTalk Interviews
Evaluating CorMedix (CRMD) Valuation As Melinta Acquisition And DefenCath Outlook Refocus Investor Attention - simplywall.st
CRMD vs. TBPH: Which Small-Cap Biotech Stock Is the Better Bet? - TradingView
Should Investors Buy, Sell or Hold CRMD Stock Ahead of Q4 Earnings? - Finviz
A Pivotal Spring Agenda for CorMedix Investors - AD HOC NEWS
CorMedix Inc. (CRMD) board approves multi-year $75M stock buyback - MSN
Understanding the Setup: (CRMD) and Scalable Risk - Stock Traders Daily
Buyback Watch: Why is CorMedix Inc stock going downMarket Growth Review & Daily Volume Surge Trade Alerts - baoquankhu1.vn
CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock? - Bitget
Why CorMedix Inc. stock attracts high net worth investorsRate Cut & Free High Return Stock Watch Alerts - mfd.ru
What is CorMedix Inc.’s book value per shareJuly 2025 Highlights & Reliable Breakout Stock Forecasts - mfd.ru
CorMedix Inc. (CRMD) Investor Outlook: 101.86% Potential Upside Sparks Interest - DirectorsTalk Interviews
Can CorMedix's Melinta acquisition aid growth beyond DefenCath? - MSN
3.69%
0.68%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):